理解发病机制与甲状腺眼病有效治疗的交叉
本文综述甲状腺眼病(TED)发病机制与治疗进展,基于PubMed检索相关文献。糖皮质激素虽广泛用于全身治疗,可减轻炎症表现,但不能可靠减少突眼和复视。其他现有疗法包括霉酚酸酯、利妥昔单抗、托珠单抗和替普罗木单抗,新策略靶向前列腺素受体、血管内皮生长因子、mTOR和胆固醇通路,恢复免疫耐受可能成为最有效安全的医疗管理。
要点
- 糖皮质激素可减轻TED炎症表现,但不能可靠减少突眼和复视。
- 现有其他疗法包括霉酚酸酯、利妥昔单抗、托珠单抗和替普罗木单抗。
- 新治疗策略靶向前列腺素受体、血管内皮生长因子、mTOR和胆固醇通路。
核心结论
- 尽管糖皮质激素目前广泛使用,但随着更有效且耐受性更好的医疗选择出现,其可能不再享有TED一线治疗地位。
- 多种现有和新兴疗法以理论和实验科学为依据,有望提供更好选择,包括替普罗木单抗、利妥昔单抗和托珠单抗。
- 恢复免疫耐受最终可能成为TED最有效且安全的医疗管理。
研究设计与样本
- 通过PubMed检索文献,检索词包括甲状腺相关眼病、甲状腺眼病、Graves眼病、自身免疫性甲状腺疾病和眶内炎症。
- 主要结局指标为科学证据强度、临床试验或观察的大小、范围和对照。
主要发现
- 糖皮质激素可减轻TED炎症相关表现,但不能可靠减少突眼和复视这两个主要致病原因。
- 其他现有疗法包括霉酚酸酯、利妥昔单抗(抗CD20 B细胞耗竭单克隆抗体)、托珠单抗(白介素-6受体拮抗剂)和替普罗木单抗(IGF-I受体抑制剂)。
- 已提出多种新治疗策略,包括靶向前列腺素受体、血管内皮生长因子、mTOR和胆固醇通路。
- 恢复免疫耐受的尝试可能具有更大的长期重要性。
关键数值与推荐
- 糖皮质激素可减轻TED炎症相关表现,但不能可靠减少突眼和复视。
- 现有其他疗法包括霉酚酸酯、利妥昔单抗、托珠单抗和替普罗木单抗。
- 新策略靶向前列腺素受体、血管内皮生长因子、mTOR和胆固醇通路。
- 恢复免疫耐受可能成为最有效且安全的医疗管理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid eye disease (TED), a vision-threatening and disfiguring autoimmune process, has thwarted our efforts to understand its pathogenesis and develop effective and safe treatments. Recent scientific advances have facilitated improved treatment options. OBJECTIVE: Review historically remote and recent advances in understanding TED. DESIGN/SETTING/PARTICIPANTS: PubMed was scanned using search terms including thyroid-associated ophthalmopathy, thyroid eye disease, Graves' orbitopathy, autoimmune thyroid disease, and orbital inflammation. MAIN OUTCOME MEASURES: Strength of scientific evidence, size, scope, and controls of clinical trials/observations. RESULTS: Glucocorticoid steroids are widely prescribed systemic medical therapy. They can lessen inflammation-related manifestations of TED but fail to reliably reduce proptosis and diplopia, 2 major causes of morbidity. Other current therapies include mycophenolate, rituximab (anti-CD20 B cell-depleting monoclonal antibody), tocilizumab (interleukin-6 receptor antagonist), and teprotumumab (IGF-I receptor inhibitor). Several new therapeutic approaches have been proposed including targeting prostaglandin receptors, vascular endothelial growth factor, mTOR, and cholesterol pathways. Of potentially greater long-term importance are attempts to restore immune tolerance. CONCLUSION: Despite their current wide use, steroids may no longer enjoy first-tier status for TED as more effective and better tolerated medical options become available. Multiple current and emerging therapies, the rationales for which are rooted in theoretical and experimental science, promise better options. These include teprotumumab, rituximab, and tocilizumab. Restoration of immune tolerance could ultimately become the most effective and safe medical management for TED.
引用
- Smith TJ. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. J Clin Endocrinol Metab. 2022. PMID: 36346686. doi:10.1210/clinem/dgac328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。